Plain language summary of a systematic review of palbociclib treatment for advanced/ metastatic breast cancer in older patients
Notice bibliographique
Résumé
Plain Language SummaryWhat is this summary about?This plain language summary is about a systematic review of articles that reported on palbociclib treatment in older patients with breast cancer who were diagnosed with a type of advanced or metastatic breast cancer called hormone receptor-positive/ human epidermal growth factor receptor 2-negative (HR+/HER2−). The patients were treated with the oral anticancer medicine, palbociclib, in combination with endocrine therapy. All of the studies included data for older populations, defined as patients aged 65 years and older (except for one study which defined the older population as patients over the age of 60). The researchers wanted to see if palbociclib plus endocrine therapy was as effective and safe for older patients with HR+/HER2− advanced/metastatic breast cancer as it was for younger patients, and if their health-related quality of life was preserved as well.What were the key findings of the systematic review?A total of 52 articles were summarized in the review: 13 articles reported on 7 different randomized clinical trials that included 437 older patients who received palbociclib plus endocrine therapy. The other 39 articles reported on 37 different real-world studies that included 7408 older patients treated with palbociclib plus endocrine therapy.In studies that compared how well palbociclib works in older and younger patients, palbociclib plus endocrine therapy showed similar benefits in both age groups. These benefits included how long a person is alive after the start of palbociclib combination treatment without their cancer getting worse (also called progression-free survival), how long a person is alive after the start of treatment (also called overall survival), and how many people had tumors that were no longer detectable or became smaller or did not grow (also called tumor response rate and clinical benefit rate). The studies that described safety and health-related quality of life as reported by the patients showed that palbociclib plus endocrine therapy was well tolerated and maintained health-related quality of life in both older and younger patients. These study findings were the same in both the clinical trials and the real-world studies.What do the findings of the systematic review mean?This systematic review is the most thorough summary to date on the use of palbociclib plus endocrine therapy to treat HR+/HER2− advanced/metastatic breast cancer in older patients. The systematic review summarizes the findings of 52 articles that provide evidence that palbociclib in combination with endocrine therapy is an effective and well tolerated treatment and preserves health-related quality of life in older patients with HR+/HER2− advanced/metastatic breast cancer. Consistent palbociclib treatment benefits were seen in both older and younger patients in clinical trials and real-world studies, lending further support for the use of palbociclib in combination with endocrine therapy in older patients with HR+/HER2− advanced/metastatic breast cancer.This is an abstract of the Plain Language Summary of Publication article.View the full Plain Language Summary PDF of this article to read the full-text
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction machine sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.
Scores du classifieur distillé par catégorie (deux têtes)
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,010 | 0,076 |
| Méta-épidémiologie (sens strict) | 0,002 | 0,002 |
| Méta-épidémiologie (sens large) | 0,009 | 0,009 |
| Bibliométrie | 0,009 | 0,011 |
| Études des sciences et des technologies | 0,001 | 0,001 |
| Communication savante | 0,004 | 0,004 |
| Science ouverte | 0,002 | 0,002 |
| Intégrité de la recherche | 0,003 | 0,002 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,036 | 0,003 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».